Juvmo Tablet
Product Images NDC 0074-6315

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Juvmo (NDC 0074-6315). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Abbvie Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

The Chemical Structure Is: The Active Ingredient Of Tradename Is Tavapadon, A Selective Dopamine D1 And D5 Receptor Partial Agonist. The Chemical Name Is (s)-1,5-dimethyl-6-(2-methyl-4-{[3-(trifluoromethyl) Pyridin-2-yl]oxy}phenyl)pyrimidine- 2,4(1h,3h)-dione. Its Molecular Formula Is C19h16f3n3o3 And Its Molecular Weight Is 391.35 Daltons. (Juvmo 01)

Chemical structure of Tavapadon, the active ingredient in JUVMO. The structure features a trifluoromethyl-pyridine moiety connected via an ether linkage to a substituted quinazolinone ring system.*

FDA Label Image

Figure 1: Study 1 Ls Mean (se) Change From Baseline In Mds-updrs Part Ii Score By Trial Visit (mitt Population) (Juvmo 02)

Line graph showing change from baseline in MDS-UPDRS Part II Total Score over 28 weeks for JUVMO 15 mg, JUVMO 5 mg, and placebo groups. The vertical axis measures change from baseline (LSMean ± SE), ranging from -3 to 1.5, and the horizontal axis shows weeks from 0 to 28. JUVMO 15 mg and 5 mg groups show a decrease (improvement) in scores compared to the placebo group, with statistical significance indicated by P < 0.0001.*

FDA Label Image

Figure 2 (Juvmo 03)

A line graph comparing the change from baseline in MDS-UPDRS Part II Total Score over 28 weeks between JUVMO and placebo groups. The x-axis represents weeks, and the y-axis shows change from baseline with error bars indicating standard error. JUVMO shows a greater decrease in scores compared to placebo, with statistical significance noted at week 28 (P = 0.0007).*

FDA Label Image

Figure 3: Ls Mean (se) Change From Baseline In On Time (hours) Without Troublesome Dyskinesia And In Off Time (hours) By Study Visit In Study 3 (mitt Population) (Juvmo 04)

A line graph showing changes from baseline in hours for 'On Time without Troublesome Dyskinesia' and 'Off Time' over 28 weeks. The graph compares JUVMO and placebo groups, with JUVMO showing increased On Time and decreased Off Time. P-values for statistical significance are noted (P < 0.0001 and P = 0.0006). Error bars indicate the standard error.*

FDA Label Image

Principal Display Panelrx Only Ndc 0074-6210-3030 Tabletsjuvmo™(tavapadon) Tablets10 mg (Juvmo 05)

Packaging label for JUVMO (tavapadon) tablets, 10 mg strength, in a kit form. The label indicates the product contains 30 tablets, is Rx only, and is marketed by AbbVie Inc. Instructions note storage conditions and the 10 mg dosage per tablet. The label includes branding, barcode, and manufacturer details.*

FDA Label Image

Principal Display Panelrx Only Ndc 0074-6105-3030 Tabletsjuvmo™(tavapadon) Tablets5 mg (Juvmo 06)

Packaging label for JUVMO (tavapadon) tablets, 5 mg strength. The label indicates it is a human prescription drug kit containing 30 tablets, marketed by AbbVie Inc. The label includes storage instructions, NDC 0074-6105-30, and the AbbVie logo on a purple background.*

FDA Label Image

Principal Display Panelrx Only Ndc 0074-6315-3030 Tabletsjuvmo™(tavapadon) Tablets15 mg (Juvmo 07)

Packaging label for JUVMO (tavapadon) tablets, 15 mg strength. The label indicates the product is marketed by AbbVie Inc. and contains 30 tablets. It includes storage instructions, a barcode, and directs users to see prescribing information for dosage details.*

FDA Label Image

Principal Display Panelndc 0074-6090-40 Rx Onlyjuvmo™(tavapadon) Tablets.25 mg Per Tablet 1 mg Per Tablet Titration Packtablets Are Packaged As 6 Weekly Cards, For A Total Of 40 Days Of Treatment.6-week Carton Contains 100 Tablets(36 X 0.25 mg Per Tablet And 64 X 1 mg Per Tablet)supplied In Weekly Blister Cards. (Juvmo 08)

JUVMO (tavapadon) tablets kit packaging label showing available strengths of 0.25 mg and 1 mg per tablet. The label identifies it as a titration pack containing 100 tablets for a 40-day treatment, supplied in weekly blister cards. The labeler is AbbVie Inc., and the NDC is 0074-6090-40.*

FDA Label Image

Principal Display Panelndc 0074-6090-40 Rx Onlyjuvmo™(tavapadon) Tablets.25 mg Per Tablet 1 mg Per Tablet Titration Packtablets Are Packaged As 6 Weekly Cards, For A Total Of 40 Days Of Treatment.6-week Carton Contains 100 Tablets(36 X 0.25 mg Per Tablet And 64 X 1 mg Per Tablet)supplied In Weekly Blister Cards. (Juvmo 09)

JUVMO (tavapadon) tablet dosing schedule kit showing a five-week titration guide with color-coded blister cards. Each week features a different tablet color and strength: Week 1 in light purple (.25 mg), Week 2 in red (1 mg), Week 3 in purple (10 mg), Week 4 in dark blue (15 mg), and Week 5 in pink (5 mg). The kit visually organizes daily dosing progression over the 5 consecutive weeks.*

FDA Label Image

Principal Display Panel21 Tablets Ndc 0074-5925-21juvmo™(tavapadon) Tablets0.25 mg Per Tabletprofessional Sample Only – Not For Sale (Juvmo 0a)

Packaging label for JUVMO (tavapadon) tablets, 0.25 mg per tablet. This professional sample pack contains 21 tablets and is marketed by AbbVie Inc. The label includes storage instructions, a barcode, and notes that the product is Rx only and not for sale.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.